Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis
about
Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytesAcylation-stimulatory activity in hyperapobetalipoproteinemic fibroblasts: enhanced cholesterol esterification with another serum basic protein, BP IIThe role of the LDL receptor in apolipoprotein B secretion.Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapyLack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolismHepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient miceMolecular mechanisms underlying the effects of statins in the central nervous system.Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and clinical evidence of hyperacute use of statins.Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease.Evaluation of plasma cholestane-3β,5α,6β-triol and 7-ketocholesterol in inherited disorders related to cholesterol metabolism.One year experience in the treatment of familial hypercholesterolaemia with simvastatinLow Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver DiseaseWolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice.Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials.Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease.Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triTargeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development.The metabolism of lipoprotein (a): an ever-evolving story.Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe.Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency.Wolman disease and its treatment.Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells.Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes.Fast progression of liver damage in lysosomal acid lipase deficiency.Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.Influence of APOA5 Locus on the Treatment Efficacy of Three Statins: Evidence From a Randomized Pilot Study in Chinese Subjects.Metabolomic strategies to identify tissue-specific effects of cardiovascular drugsAssociation of LIPA Gene Polymorphisms With Obesity-Related Metabolic Complications Among Severely Obese Patients
P2860
Q24812046-CA13FD4F-D447-4E8B-BE21-C4DE2A8E148AQ28569109-8F28EAFB-B449-472B-A839-C6B2E2C96820Q33900333-077743C6-9CDE-4225-8179-64B6DBB408E4Q33939089-0484C206-FEAA-48CA-B1C3-350B9F50CA71Q33940346-C093672E-9DF1-4DAC-971C-882BE7C0590CQ34137441-403A2AE1-7C18-46F9-B6BE-573665F578B3Q34260272-4B288B0E-0B32-4B66-9512-C390BB3F3D92Q34356070-26FCADB2-9FD0-4AE4-93E8-45AB55AA1276Q34685463-D539BF5C-A496-4405-B645-C2B0A67236DBQ34729472-79A74BAC-E031-4351-98D2-03CECF2E4D43Q35182920-B0A5D10C-2211-4464-937B-2440220B5F5AQ36617431-80610BC1-22B7-4164-9139-5EABB884D6E5Q36682706-DC830861-BF41-4FBD-9975-9E5C96E5DE17Q36743546-C5714D20-CA9A-4C10-9F5E-EDEC59395D6FQ36745074-B3F7784E-82D5-40F0-ABC3-E7FEBF16347CQ36806626-A39F1F5F-1F3D-4B4C-988C-8E11B6B851E6Q37057100-239C566C-4344-4895-87B9-6E0F980CE9BDQ37604513-A773E1A2-933A-4523-B115-044404F2A16CQ37705070-3E55BAC6-3500-48C3-B145-5FF137FF9550Q37717441-FA7730DF-CA1B-42E8-B15D-0607A40C1CFAQ38655614-9CEF92FB-0B68-4F42-A097-2E10969A549BQ38891202-DD45B777-47A3-486D-99AF-C42145CC25E3Q39136059-761C8979-7797-4604-806A-2175CDE9BA66Q40549567-4BF8310A-709F-490A-9AAB-1C4573EE8331Q42482221-4FBB55E5-5FE5-4E9C-96A3-E042D7408B09Q44272184-16A750C5-F0F9-4633-9010-869A3ECD846BQ45868093-D7826AC3-8BEF-488B-91B2-ED3C7DE8B2FAQ46703453-B205C977-834F-4CDE-BDFE-98D2774BF0CDQ55017020-9CD1D6D2-7931-43E6-8A15-474C8EB9E48AQ57012269-DA14584C-CD2D-449E-A00E-F8003C5EC2B6Q57316293-5C010FBD-22B1-499F-9C7B-A84568EEBC83
P2860
Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Suppression of apolipoprotein ...... of apolipoprotein B synthesis
@ast
Suppression of apolipoprotein ...... of apolipoprotein B synthesis
@en
type
label
Suppression of apolipoprotein ...... of apolipoprotein B synthesis
@ast
Suppression of apolipoprotein ...... of apolipoprotein B synthesis
@en
prefLabel
Suppression of apolipoprotein ...... of apolipoprotein B synthesis
@ast
Suppression of apolipoprotein ...... of apolipoprotein B synthesis
@en
P2093
P2860
P356
P1476
Suppression of apolipoprotein ...... of apolipoprotein B synthesis
@en
P2093
H N Ginsberg
R J Desnick
R Ramakrishnan
P2860
P304
P356
10.1172/JCI113259
P407
P577
1987-12-01T00:00:00Z